CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 102 filers reported holding CYMABAY THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.55 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $171,671 | -70.3% | 19,687 | -78.6% | 0.00% | -66.7% |
| Q4 2022 | $577,498 | +175.0% | 92,105 | +53.4% | 0.00% | +200.0% |
| Q3 2022 | $210,000 | +288.9% | 60,024 | +230.5% | 0.00% | – |
| Q2 2022 | $54,000 | -58.5% | 18,162 | -19.8% | 0.00% | -100.0% |
| Q4 2020 | $130,000 | -71.3% | 22,658 | -63.8% | 0.00% | -66.7% |
| Q3 2020 | $453,000 | +1158.3% | 62,577 | +514.5% | 0.01% | +500.0% |
| Q2 2020 | $36,000 | – | 10,183 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,629,464 | $14,208,926 | 10.61% |
| Lynx1 Capital Management LP | 1,369,927 | $11,945,763 | 9.96% |
| Versant Venture Management, LLC | 543,753 | $4,741,526 | 9.88% |
| Foresite Capital Management IV, LLC | 1,787,094 | $15,583,460 | 8.09% |
| Octagon Capital Advisors LP | 4,570,918 | $39,858,405 | 5.74% |
| ACUTA CAPITAL PARTNERS, LLC | 878,500 | $7,660,520 | 5.64% |
| TCG Crossover Management, LLC | 3,048,257 | $26,580,801 | 5.18% |
| Affinity Asset Advisors, LLC | 1,083,118 | $9,444,789 | 3.12% |
| Altium Capital Management LP | 620,000 | $5,406,400 | 3.00% |
| Bain Capital Life Sciences Investors, LLC | 2,500,000 | $21,800 | 2.72% |